-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 7, CDE issued the "Technical Guidelines for Non-clinical Pharmacodynamic Research and Evaluation of Anti-coronavirus Chemical Drugs (Trial)" and "Technical Guidelines for Non-clinical Pharmacodynamic Research and Evaluation of Anti-coronavirus Pneumonia Drugs (Trial)" The "Technical Guidelines for Non-clinical Research on Novel Coronavirus Neutralizing Antibody Drugs (Trial)" will come into effect on the date of issuance
The original text is as follows:
The original text is as follows:The Center for Drug Evaluation of the National Food and Drug Administration on the release of "Technical Guidelines for Non-clinical Pharmacodynamic Research and Evaluation of Anti-coronavirus Chemical Drugs (Trial)" and "Technical Guidelines for Non-clinical Pharmacodynamic Research and Evaluation of Anti-coronavirus Pneumonia Inflammatory Drugs (Trial) ) "Notice of "Technical Guidelines for Non-clinical Research of Novel Coronavirus Neutralizing Antibody Drugs (Trial)" (No.
In view of the occurrence and development of the domestic and international new crown epidemic and the needs of clinical treatment, anti-new crown virus chemical drugs, treatment of new crown virus pneumonia inflammation drugs and new crown virus neutralizing antibody drugs have become the focus of anti-epidemic drug development and review
Appendix:
1.
Technical guidelines for non-clinical pharmacodynamic research and evaluation of anti-new coronavirus chemical drugs (for trial implementation)
2.
Technical guidelines for non-clinical pharmacodynamic research and evaluation of anti-new coronavirus pneumonia inflammatory drugs (for trial implementation)
3.
Technical guidelines for non-clinical research of new coronavirus neutralizing antibody drugs (for trial implementation)